Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol augmentation of exposure therapy for treatment-refractory phobic anxiety disorders
NL-OMON44760Phase 3Active, not recruiting
- Sponsor
- Utrecht University
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Social Anxiety Disorder (SAD), Agoraphobia with panic disorder (PD/A) and specific phobia comparing Cannabidiol + ERP with Placebo + ERP (2 arms). Primary endpoint: Change in anxiety symptoms over treatment and follow-up. Started Feb 2016; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
Social Anxiety Disorder (SAD)Agoraphobia with panic disorder (PD/A)specific phobia
Beyond the preview
Go deeper on NL-OMON44760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44760.